PTC THERAPEUTICS INC (PTCT) Stock Price, Quote, News and Overview
NASDAQ:PTCT - Nasdaq - US69366J2006 - Common Stock - Currency: USD
PTCT Quote, Performance and Key Statistics
PTC THERAPEUTICS INC
NASDAQ:PTCT (2/4/2025, 8:02:57 PM)
Premarket: 48.4 -0.98 (-1.98%)49.38
-0.63 (-1.26%)
The current stock price of PTCT is 49.38 USD. In the past month the price increased by 6.1%. In the past year, price increased by 93.57%.
PTCT Latest News, Press Releases and Analysis
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each...
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D.,...
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 43rd Annual J.P. Morgan Healthcare...
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of...
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an...
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.
PTCT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 14.58 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About PTCT
Company Profile
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 988 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The firm has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Company Info
PTC THERAPEUTICS INC
500 Warren Corporate Center Drive
WARREN NEW JERSEY 07080 US
CEO: Stuart W. Peltz
Employees: 1022
Company Website: https://www.ptcbio.com/
Investor Relations: https://ir.ptcbio.com/
Phone: 19082227000
PTCT FAQ
What is the stock price of PTCT?
The current stock price of PTCT is 49.38 USD.
What is the symbol for PTC THERAPEUTICS INC stock?
The exchange symbol of PTC THERAPEUTICS INC is PTCT and it is listed on the Nasdaq exchange.
On which exchange is PTCT stock listed?
PTCT stock is listed on the Nasdaq exchange.
Is PTCT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PTCT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PTCT.
Does PTCT stock pay dividends?
PTCT does not pay a dividend.
When does PTCT stock report earnings?
PTCT will report earnings on 2025-02-25, after the market close.
What is the Price/Earnings (PE) ratio of PTCT?
PTCT does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.1).
What is the Short Interest ratio of PTCT stock?
The outstanding short interest for PTCT is 5.63% of its float.
PTCT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PTCT. When comparing the yearly performance of all stocks, PTCT is one of the better performing stocks in the market, outperforming 93.64% of all stocks.
PTCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PTCT. Both the profitability and financial health of PTCT have multiple concerns.
PTCT Financial Highlights
Over the last trailing twelve months PTCT reported a non-GAAP Earnings per Share(EPS) of -4.1. The EPS increased by 49.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTCT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to PTCT. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 26.94% and a revenue growth -14.97% for PTCT